Replies to post #535 on Resverlogix Corp. (RVXCF)

[cabel]

In the link i read this:

Looking ahead, the company’s next focus will be releasing top-line data from the trial by the end of the year and has already set up licensing structures for the drug, Apabetalone. One is with Shenzhen Hepalink Pharmaceutical in China, and another with Medison Pharma in Israel—both deals could bring the company over C$500 million in revenue. Following regulatory milestones the company is ready for global commercialization.

Are these 2 deals for only part of the world market,...?